# US 2016/0355860 A1 · Crz1 mutant fungal cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0355860 A1
- Document ID: US20160355860A1
- Status: Published application
- Kind: A1
- Application number: 15/243,268
- Filed: 2016-08-22
- Published: 2016-12-08
- Earliest claimed: 2012-10-22
- Assignees: Merck Sharp & Dohme Corp.
- Applicants: Merck Sharp & Dohme Corp.
- Inventors: Bo Jiang; Jun Zhuang
- Web page: https://patentgrep.com/patent/US20160355860A1

## CPC

- C12P 21/00: Preparation of peptides or proteins (single cell protein C12N1/00)
- C07K 14/39: from yeasts
- C07K 16/00: Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C12N 15/80: for fungi
- C12N 15/81: for yeasts
- C12N 15/815: {for yeasts other than Saccharomyces}
- C12P 21/02: having a known sequence of two or more amino acids, e.g. glutathione
- C07K 2317/14: Specific host cells or culture conditions, e.g. components, pH or temperature
- C12P: FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE {(brewing of beer C12C; producing vinegar C12J; producing specific peptides or proteins C07K; producing enzymes C12N9/00; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; measuring or testing processes involving enzymes or microorganisms C12Q; measuring or testing processes involving nucleic acid amplification reactions C12Q1/6844; fermentation processes to form a food composition, A21 or A23; compounds in general, see the relevant compound class, e.g. C01, C07)}
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention provides CRZ1 mutant fungal host cells, such as Pichia pastoris. The mutant fungal host cells exhibit temperature-resistance, enhanced fermentation robustness and increased expression of heterologous polypeptides such as immunoglobulins. Methods for producing heterologous polypeptides, such as immunoglobulins, using such mutant fungal host cells are within the scope of the present invention.

## Claims

### Claim 1

An isolated fungal host cell lacking functional CRZ1 polypeptide with the proviso that the cell comprises functional ATT1 polypeptide.

### Claim 2 (depends on 1)

The isolated fungal host cell of claim 1:
wherein endogenous CRZ1 is mutated, disrupted, partially deleted or fully deleted; or,
wherein CRZ1 polypeptide expression is reduced by interfering with CRZ1 transcription or CRZ1 translation or wherein CRZ1 polypeptide degradation is increased; or,
wherein CRZ1 polypeptide activity is inhibited by chemical inhibitor.

### Claim 3 (depends on 1, 2)

The isolated fungal host cell of any of claims 1-2 wherein:
(i) endogenous CRZ1 encodes a polypeptide that differs from wild-type CRZ1 in that comprises one or more mutations selected from the group consisting of:
L33→STOP;
Q214→STOP;
L294→STOP;
S298→STOP;
E403→G;
F406→S;
F406→L;
C411F; and
K469N; or
(ii) endogenous CRZ1 comprises a nucleotide sequence that differs from wild-type CRZ1 in that it comprises one or more mutations selected from the group consisting of:
a1407c;
g1232t
t1216c;
t1217c;
a 1208g
c893a;
t881 g;
c640t; and
t98a; or
(iii) endogenous CRZ1 differs from wild-type CRZ1 in that it does not encode a functional C-terminal zinc-finger domain.

### Claim 4 (depends on 1, 2, 3)

The isolated fungal host cell of any of claims 1-3:
(i) wherein one or more endogenous beta-mannosyltransferase genes are mutated, disrupted, truncated or partially or fully deleted;
(ii) comprising a polynucleotide encoding an alpha-1,2 mannosidase enzyme;
(iii) wherein one or more endogenous phosphomannosyl transferases are mutated, disrupted, truncated or partially or fully deleted;
(iv) comprising a single-subunit oligosaccharyltransferase;
(v) wherein endogenous ALG3 is mutated, disrupted, truncated or partially or fully deleted;
(vi) comprising a polynucleotide encoding an endomannosidase;
(vii) comprising one or more polynucleotides encoding a bifunctional UDP-N-acetylglucosamine-2-epimerase/N-acetylmannosamine kinase, an N-acetylneuraminate-9-phosphate synthase, or a CMP-sialic acid synthase;
(viii) wherein endogenous ATT1 gene is mutated, disrupted, truncated or partially or fully deleted;
(ix) wherein endogenous OCH1 is mutated, disrupted, truncated or partially or fully deleted;
(x) comprising a polynucleotide encoding galactosyltransferase;
(xi) comprising a polynucleotide encoding nucleotide sugar transporter;
(xii) comprising a polynucleotide encoding sialyltransferase;
(xiii) comprising a polynucleotide encoding acetylglucosaminyl transferase; and/or
(xiv) wherein one or more endogenous proteases are mutated, disrupted, truncated or partially or fully deleted.

### Claim 5 (depends on 1, 2, 3, 4)

The isolated fungal host cell of any of claims 1-4 comprising a heterologous polynucleotide that encodes a heterologous polypeptide.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The isolated fungal host cell of any of claims 1-5 wherein the heterologous polypeptide is an immunoglobulin.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The isolated fungal host cell of any of claims 1-6 which is yeast, methylotrophic yeast, Pichia or Pichia pastoris.

### Claim 8

An isolated polynucleotide which encodes a polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 3 which comprises a mutation selected from the group consisting of:
L33→STOP;
Q214→STOP;
L294→STOP;
S298→STOP;
E403→G;
F406→S;
F406→L;
C411 -F; and
K469→N.

### Claim 9 (depends on 8)

The polynucleotide of claim 8 comprising a nucleotide sequence of SEQ ID NO: 2 comprising a mutation selected from the group consisting of:
a1407c;
g1232t;
t1216c;
t1217c;
al208g;
c893a;
t881 g;
c640t; and
t98a.

### Claim 10 (depends on 8, 9)

An isolated vector comprising a polynucleotide of any of claims 8-9.

### Claim 11

A method for producing an isolated fungal cell having improved viability under bioprocess fermentation conditions comprising introducing a mutation selected from the group consisting of:
L33→STOP;
Q214→STOP;
L294→STOP;
S298→STOP;
E403→G;
F406→S;
F406→L;
C411→F; and
K469-N;
to endogenous CRZ1 in the fungal cell.

### Claim 12 (depends on 11)

An isolated fungal host cell produced by the method of claim 11.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7)

A method for making the isolated fungal host cell of any of claims 1-7 comprising introducing a heterologous polynucleotide into the cell which homologously recombines with the endogenous CRZ1 and partially or fully deletes the endogenous CRZ1 or disrupts the endogenous CRZ1.

### Claim 14 (depends on 13)

An isolated fungal host cell produced by the method of claim 13.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 12, 14)

A method for producing one or more heterologous polypeptides comprising:
(i) introducing a heterologous polynucleotide encoding the heterologous polypeptide(s) into an isolated fungal host cell of any of claims 1-7, 12 and 14; and
(ii) culturing the fungal host cell under conditions favorable to expression of the heterologous polypeptide(s) in the fungal host cell and, optionally,
(iii) isolating the heterologous polypeptide(s) from the fungal host cell.

### Claim 16 (depends on 15)

The method of claim 15 wherein the heterologous polynucleotide that encodes the heterologous polypeptide is operably linked to a methanol inducible promoter and wherein the isolated fungal host cell is cultured under conditions favorable to expression of the heterologous polypeptide in the presence of methanol.
